Dr. Bateman is a leading Alzheimer’s Disease researcher, and a longtime partner in GHR's Alzheimer’s prevention efforts. In 2020, he was elected to the National Academy of Medicine – a part of the National Academy of Sciences, to which membership is considered one of the highest honors in the fields of health and medicine in the United States.
Dr. Bateman established the the Dominantly Inherited Alzheimer Network (DIAN), an international research partnership focused on families with genetic mutations that cause early onset Alzheimer’s disease. GHR has partnered with Dr. Bateman testing several potential prevention therapies in clinical trials.
GHR has also partnered with Dr. Bateman on the development of the world’s first blood test for Alzheimer’s Disease. Dr. Bateman’s invention is being commercialized by C2N Diagnostics as the PrecivityAD family of tests. PrecivityAD received a breakthrough device designation from the FDA and represents a significant innovation for patients, advocates, and physicians who have long awaited an easy to administer test that can improve the accuracy of an Alzheimer’s Disease diagnosis.